deltatrials
Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT02655471

Effect of Raltegravir in Patients With Acute Tropical Spastic Paraparesis - Human T-Lymphotropic Virus 1 Infection

Effect of Raltegravir in Patients With Myelopathy/Tropical Spastic Paraparesis Associated With Infection by Human T-Lymphotropic Virus 1 (HTLV-1). Pilot Study

Sponsor: Merck Sharp & Dohme LLC

Conditions HTLV-I Infections Tropical Spastic Paraparesis
Interventions Raltegravir and Zidovudine
Updated 9 times since 2017 Last updated: May 20, 2019 Started: Jul 1, 2017 Primary completion: Mar 15, 2019 Completion: Mar 15, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates HTLV-I Infections and Tropical Spastic Paraparesis and is currently completed. Merck Sharp & Dohme LLC leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotNot Yet Recruiting~Feb 2017 – ~Dec 2017 · 10 months · monthly snapshotNot Yet Recruiting~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshotRecruiting~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshotRecruiting~Jun 2019 – ~Jan 2021 · 19 months · monthly snapshotCompleted~Jan 2021 – ~Jun 2022 · 17 months · monthly snapshotCompleted~Jun 2022 – ~Jul 2024 · 25 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed EARLY_PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed EARLY_PHASE1

  3. Jun 2022 — Jul 2024 [monthly]

    Completed EARLY_PHASE1

  4. Jan 2021 — Jun 2022 [monthly]

    Completed EARLY_PHASE1

  5. Jun 2019 — Jan 2021 [monthly]

    Completed EARLY_PHASE1

    Status: Recruiting → Completed

▶ Show 4 earlier versions

  1. Jun 2018 — Jun 2019 [monthly]

    Recruiting EARLY_PHASE1

  2. Dec 2017 — Jun 2018 [monthly]

    Recruiting EARLY_PHASE1

    Status: Not Yet Recruiting → Recruiting

  3. Feb 2017 — Dec 2017 [monthly]

    Not Yet Recruiting EARLY_PHASE1

    Phase: Phase 0 → EARLY_PHASE1

  4. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting Phase 0

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Merck Sharp & Dohme LLC
  • Universidad Peruana Cayetano Heredia
Data source: Universidad Peruana Cayetano Heredia

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations